Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $57.8 million.

  • Q32 Bio's Liabilities and Shareholders Equity fell 4472.65% to $57.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.3 million, marking a year-over-year decrease of 3102.63%. This contributed to the annual value of $92.3 million for FY2024, which is 9621.31% up from last year.
  • Q32 Bio's Liabilities and Shareholders Equity amounted to $57.8 million in Q3 2025, which was down 4472.65% from $66.1 million recorded in Q2 2025.
  • Over the past 5 years, Q32 Bio's Liabilities and Shareholders Equity peaked at $311.0 million during Q1 2022, and registered a low of $47.1 million during Q4 2023.
  • For the 5-year period, Q32 Bio's Liabilities and Shareholders Equity averaged around $171.2 million, with its median value being $169.3 million (2023).
  • As far as peak fluctuations go, Q32 Bio's Liabilities and Shareholders Equity plummeted by 7940.34% in 2023, and later surged by 9621.31% in 2024.
  • Over the past 5 years, Q32 Bio's Liabilities and Shareholders Equity (Quarter) stood at $211.7 million in 2021, then increased by 7.91% to $228.5 million in 2022, then crashed by 79.4% to $47.1 million in 2023, then surged by 96.21% to $92.3 million in 2024, then tumbled by 37.42% to $57.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $57.8 million in Q3 2025, compared to $66.1 million in Q2 2025 and $79.1 million in Q1 2025.